韩国食品药品安全部周四公布政府数据显示，受欧洲市场旺盛需求拉动，今年前9个月韩国生物制药产品出口额创下66亿美元的新高。
1–9月，韩国生物制药出口额同比增长15.8%，预估达66亿美元。
该数据显示，这一部分出口额约占同期韩国医药产品总出口额90亿美元的73%。
仅第三季度，生物制药出口额同比上涨15.6%，至20.7亿美元。
前9个月，美国为韩国第一大出口目的地，出口规模10.7亿美元，占生物制药出口总额的16.3%。
瑞士位列第二，出口额10.1亿美元；匈牙利以9.2亿美元排在第三位。
对欧出口增长尤为亮眼，韩国生物制药十大出口目的地中有七个位于欧洲。增长部分得益于合同研发生产）服务与生物类似药的强劲市场需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.